ATE536553T1 - Verfahren zum nachweis grösserer ungünstiger kardiovaskulärer und zerebrovaskulärer ereignisse - Google Patents
Verfahren zum nachweis grösserer ungünstiger kardiovaskulärer und zerebrovaskulärer ereignisseInfo
- Publication number
- ATE536553T1 ATE536553T1 AT08837800T AT08837800T ATE536553T1 AT E536553 T1 ATE536553 T1 AT E536553T1 AT 08837800 T AT08837800 T AT 08837800T AT 08837800 T AT08837800 T AT 08837800T AT E536553 T1 ATE536553 T1 AT E536553T1
- Authority
- AT
- Austria
- Prior art keywords
- adverse cardiovascular
- major adverse
- human
- cerebrovascular events
- cerebrovascular event
- Prior art date
Links
- 230000002411 adverse Effects 0.000 title abstract 4
- 230000002526 effect on cardiovascular system Effects 0.000 title 1
- 230000007211 cardiovascular event Effects 0.000 abstract 3
- 230000007213 cerebrovascular event Effects 0.000 abstract 3
- 102000005720 Glutathione transferase Human genes 0.000 abstract 1
- 108010070675 Glutathione transferase Proteins 0.000 abstract 1
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 abstract 1
- 102100023123 Mucin-16 Human genes 0.000 abstract 1
- 102000002262 Thromboplastin Human genes 0.000 abstract 1
- 108010000499 Thromboplastin Proteins 0.000 abstract 1
- 102000013529 alpha-Fetoproteins Human genes 0.000 abstract 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
- H01J49/00—Particle spectrometers or separator tubes
- H01J49/0009—Calibration of the apparatus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/745—Assays involving non-enzymic blood coagulation factors
- G01N2333/7454—Tissue factor (tissue thromboplastin, Factor III)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
- Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
- Electrotherapy Devices (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99856307P | 2007-10-10 | 2007-10-10 | |
| US99875607P | 2007-10-11 | 2007-10-11 | |
| PCT/US2008/079553 WO2009049189A2 (en) | 2007-10-10 | 2008-10-10 | Methods for detecting major adverse cardiovascular and cerebrovascular events |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE536553T1 true ATE536553T1 (de) | 2011-12-15 |
Family
ID=40289424
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT08837800T ATE536553T1 (de) | 2007-10-10 | 2008-10-10 | Verfahren zum nachweis grösserer ungünstiger kardiovaskulärer und zerebrovaskulärer ereignisse |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20110045514A1 (de) |
| EP (1) | EP2210108B1 (de) |
| JP (1) | JP2011501133A (de) |
| CN (1) | CN101939651A (de) |
| AT (1) | ATE536553T1 (de) |
| AU (1) | AU2008310669A1 (de) |
| CA (1) | CA2702268A1 (de) |
| ES (1) | ES2374762T3 (de) |
| IL (1) | IL204922A0 (de) |
| WO (1) | WO2009049189A2 (de) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8620738B2 (en) * | 2006-08-31 | 2013-12-31 | Visa U.S.A. Inc | Loyalty program incentive determination |
| GB0717637D0 (en) | 2007-09-10 | 2007-10-17 | Univ Leiden | Future cardiac event biomarkers |
| EP2199956A1 (de) * | 2008-12-18 | 2010-06-23 | Siemens Aktiengesellschaft | Verfahren und System zum Verwalten von Ergebnissen eines Analyseverfahrens an Gegenständen, die entlang einer technischen Verfahrenslinie gehandhabt werden |
| EP2499489B1 (de) | 2009-11-13 | 2015-01-07 | BG Medicine, Inc. | Risikofaktoren und vorhersage von myokardinfarkt |
| CA3012137A1 (en) * | 2010-01-29 | 2011-08-04 | Metanomics Gmbh | Means and methods for diagnosing heart failure in a subject |
| ES2728120T3 (es) * | 2010-01-29 | 2019-10-22 | Metanomics Gmbh | Medios y procedimientos para diagnosticar insuficiencia cardíaca en un sujeto |
| EP2617052B1 (de) * | 2010-09-15 | 2022-06-08 | DH Technologies Development Pte. Ltd. | Datenunabhängige erfassung von produktionsspektren und abgleich mit einer referenzspektrenbibliothek |
| EP2592422A1 (de) * | 2011-11-08 | 2013-05-15 | Zora Biosciences OY | Lipidomik-Biomarker zur Prognose von kardiosvaskulären Ergebnissen bei Patienten mit Erkrankung der Herzkranzgefäße unter Statinbehandlung |
| EP3968026A1 (de) * | 2012-03-26 | 2022-03-16 | XCellCure, LLC | Vorrichtung und verfahren zur erkennung von analyten |
| WO2014144129A2 (en) * | 2013-03-15 | 2014-09-18 | Sera Prognostics, Inc. | Biomarkers and methods for predicting preterm birth |
| KR101660328B1 (ko) | 2014-01-14 | 2016-09-27 | 한국과학기술연구원 | 심혈관 질환 진단용 바이오 마커 |
| BR112016023418A8 (pt) | 2014-04-10 | 2019-12-10 | MEP Equine Solutions LLC | método e kit para a quantificação de ovos de parasitas nas fezes |
| CA2955374A1 (en) * | 2014-07-18 | 2016-01-21 | Genova Diagnostics, Inc. | Use of an evidence-based, translational algorithm to, inter alia, assess biomarkers |
| US20180238914A1 (en) * | 2015-08-19 | 2018-08-23 | Metanomics Gmbh | Means and methods for diagnosing cardiac disease in a subject |
| CN108027354B (zh) * | 2015-08-20 | 2021-01-08 | 深圳华大生命科学研究院 | 冠心病的生物标志物 |
| CN105223264B (zh) * | 2015-09-21 | 2017-12-29 | 广东联捷生物科技有限公司 | 一种质谱定量分析的模拟内标方法、装置及应用 |
| CN105445408B (zh) * | 2016-01-25 | 2018-06-12 | 齐炼文 | 诊断区分冠状动脉粥样硬化和稳定型心绞痛的代谢标志物 |
| CN105486778B (zh) * | 2016-01-25 | 2017-11-03 | 齐炼文 | 诊断区分稳定型心绞痛和急性冠脉综合征的代谢标志物 |
| CN105866261A (zh) * | 2016-03-24 | 2016-08-17 | 中国药科大学 | 诊断区分稳定型心绞痛和急性冠脉综合征的代谢标志物群 |
| EP3443352A1 (de) | 2016-04-14 | 2019-02-20 | Roche Diagnostics GmbH | Verfahren zur bestimmung einer konzentration eines analyten in einer körperflüssigkeitsprobe |
| EP4545968A2 (de) * | 2017-12-13 | 2025-04-30 | GLX Analytix ApS | Biomarker für multiple sklerose |
| WO2020054721A1 (ja) * | 2018-09-12 | 2020-03-19 | 株式会社島津製作所 | 心房細動指標値の測定方法 |
| CN109799296A (zh) * | 2019-01-28 | 2019-05-24 | 江南大学 | 一种用于细胞非靶向代谢组学分析的样品前处理方法 |
| WO2021212082A1 (en) * | 2020-04-17 | 2021-10-21 | The Regents Of The University Of California | Systems and methods for classifying critical heart defects |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| EP1904846A4 (de) * | 2005-06-29 | 2009-03-18 | Rules Based Medicine Inc | Verfahren und kits zur diagnose von akutem koronarsyndrom |
| WO2007124439A2 (en) * | 2006-04-21 | 2007-11-01 | Rules-Based Medicine, Inc. | Diagnosis of stroke using metalloproteinase or transaminase |
-
2008
- 2008-10-10 CA CA2702268A patent/CA2702268A1/en not_active Abandoned
- 2008-10-10 CN CN2008801210762A patent/CN101939651A/zh active Pending
- 2008-10-10 WO PCT/US2008/079553 patent/WO2009049189A2/en not_active Ceased
- 2008-10-10 JP JP2010529096A patent/JP2011501133A/ja not_active Withdrawn
- 2008-10-10 US US12/682,492 patent/US20110045514A1/en not_active Abandoned
- 2008-10-10 AU AU2008310669A patent/AU2008310669A1/en not_active Abandoned
- 2008-10-10 AT AT08837800T patent/ATE536553T1/de active
- 2008-10-10 EP EP08837800A patent/EP2210108B1/de not_active Not-in-force
- 2008-10-10 ES ES08837800T patent/ES2374762T3/es active Active
-
2010
- 2010-04-08 IL IL204922A patent/IL204922A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009049189A3 (en) | 2009-06-18 |
| CA2702268A1 (en) | 2009-04-16 |
| ES2374762T3 (es) | 2012-02-21 |
| AU2008310669A1 (en) | 2009-04-16 |
| US20110045514A1 (en) | 2011-02-24 |
| CN101939651A (zh) | 2011-01-05 |
| WO2009049189A2 (en) | 2009-04-16 |
| EP2210108A2 (de) | 2010-07-28 |
| IL204922A0 (en) | 2010-11-30 |
| JP2011501133A (ja) | 2011-01-06 |
| EP2210108B1 (de) | 2011-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE536553T1 (de) | Verfahren zum nachweis grösserer ungünstiger kardiovaskulärer und zerebrovaskulärer ereignisse | |
| Jia et al. | Diagnosis accuracy of serum glypican-3 in patients with hepatocellular carcinoma: a systematic review with meta-analysis | |
| NZ593514A (en) | p-mTOR and p-AKT as Ratio Based Biomarkers for the Prognosis and/or Diagnosis of Cancer | |
| ATE548656T1 (de) | Verfahren zur identifizierung von patienten mit erhöhter wahrscheinlichkeit des auftretens eines ovarialkarzinoms und zusammensetzungen dafür | |
| BR112014016158A2 (pt) | medições exatas de analito para tira de teste eletroquímica com base na(s) característica(s) física(s) detectada(s) da amostra contendo o analito | |
| TW200617380A (en) | Concentration determination in a diffusion barrier layer | |
| CA2701341A1 (en) | Method of assessing colorectal cancer from a stool sample by use of the marker combination calprotectin and hemoglobin/haptoglobin complex | |
| MX2007014815A (es) | Metodos de inmunoanalisis mejorados. | |
| AR103935A1 (es) | Métodos de detección y cuantificación de il-13 y sus usos en el diagnóstico y tratamiento de enfermedades asociadas a th-2 | |
| RU2008136193A (ru) | Детектирование рака по повышенным уровням bcl-2 | |
| WO2009137015A3 (en) | Biomarkers of ionizing radiation | |
| BR112013003391B8 (pt) | Método para diagnosticar câncer pancreático em um indivíduo | |
| JPWO2016163539A1 (ja) | 肝疾患の病態を判別する方法 | |
| IN2015DN01855A (de) | ||
| DE60332639D1 (de) | Verwendung von biomarkern zum nachweis von eierstockkrebs | |
| EP2569635A4 (de) | Verfahren zur diagnose und/oder behandlung von enzephalitis oder epilepsie | |
| DE60129151D1 (de) | Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6) | |
| ATE492815T1 (de) | Diagnostik-biomolekül(e) | |
| RU2019104870A (ru) | Комбинированный тест на наличие колоректального рака | |
| ATE370414T1 (de) | Verwendung von nicotinamide n-methyltransferase zur diagnose von kolorektalem krebs | |
| MX2012007009A (es) | Método para diagnosticar un tumor maligno. | |
| DE602005014386D1 (de) | Verwendung von cyfra 21-1 und osteopontin als marker für kolorektalkarzinome | |
| DE602007006671D1 (de) | Verwendung von nnmt als marker für lungenkrebs | |
| ATE503846T1 (de) | Verfahren zur diagnose eines ovarialkarzinoms | |
| CY1109461T1 (el) | Βελτιωμενες μεθοδοι ανοσολογικου προσδιορισμου |